TABLE 1.
Protection against a challenge M. tuberculosis infection in CD4−/− mice reconstituted with CD4+ T cells and vaccinated with Ag85B DNAa
| Mouse treatment parameter | Log10 mRLU (SD)b
|
|||||
|---|---|---|---|---|---|---|
| Spleen
|
Lungs
|
|||||
| WT (4 wk) | CD4−/− (4 wk) | CD4−/− (8 wk) | WT (4 wk) | CD4−/− (4 wk) | CD4−/− (8 wk) | |
| Naive (n = 4) | 3.57 (0.13) | 4.72 (0.29) | 4.74 (0.47) | 4.80 (0.17) | 5.08 (0.40) | 5.45 (0.07) |
| Ag85B DNA (n = 4) | 3.42 (0.03) | 4.96 (0.39) | 5.33 (0.14) | 4.20 (0.34)* | 4.75 (0.40) | 5.25 (0.30) |
| BCG (n = 4) | 3.43 (0.09) | 3.73 (0.26)** | ND | 3.71 (0.13)** | 3.80 (0.30)** | ND |
| AT (20 × 106 CD4+ T cells) (n = 3) | 4.37 (0.14) | 4.49 (0.14) | 5.24 (0.16) | 5.40 (0.10) | ||
| AT (20 × 106 CD4+ T cells) + control DNA (n = 4) | ND | 4.58 (0.3) | ND | 5.63 (0.22) | ||
| AT (5 × 106 CD4+ T cells) + Ag85B DNA (n = 4) | 4.57 (0.15) | ND | 5.17 (0.33) | ND | ||
| AT (20 × 106 CD4+ T cells) + Ag85B DNAc | 4.28 (0.38)* | 4.1 (0.24)** | 5.22 (0.29) | 5.05 (0.50) | ||
a
Eight weeks after the third dose of pDNA vaccination and 8 weeks after BCG vaccination, mice received a luminescent M. tuberculosis challenge (2 × 105 CFU = 5 log10 mRLU/mouse, intravenously). Four and eight weeks later, viable bacterial counts in spleen and lungs were determined by luminescence.
b
*, P < 0.05; **, P <0.01 (compared to Ag85B DNA-vaccinated CD4−/− mice for reconstituted CD4−/− mice and compared to naïve mice for the other groups); ND, not done.
c
n = 5 at 4 weeks; n = 4 at 8 weeks.